Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population

Published:August 18, 2016DOI:

      Background & Aims

      The number of people living with previous hepatitis C infection that have attained a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group relative to the general population is unclear.


      Individuals attaining SVR in Scotland in 1996–2011 were identified using a national database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. We calculated standardised mortality ratios (SMRs) to compare the frequency of mortality in SVR patients to the general population. In a parallel analysis, we used Cox regression to identify modifiable patient characteristics associated with post-SVR mortality.


      We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than the general population (SMR: 1.86; 95% confidence interval (CI): 1.49–2.32). Significant cause-specific elevations were seen for death due to primary liver cancer (SMR: 23.50; 95% CI: 12.23–45.16), and death due to drug-related causes (SMR: 6.58, 95% CI: 4.15–10.45). Together these two causes accounted for 66% of the total excess death observed. All of the modifiable characteristics associated with increased mortality were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 95% CI: 0.41–1.18)


      Mortality in Scottish SVR patients is higher overall than the general population. The excess was driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as important modifiable determinants of mortality in this population.

      Lay summary

      Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. A history of heavy alcohol and injecting drug use were associated with a higher mortality risk.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pawlotsky J.-M.
        New hepatitis C therapies: the toolbox, strategies and challenges.
        Gastroenterology. 2014; 146: 1176-1192
        • Pawlotsky J.-M.
        • Feld J.J.
        • Zeuzem S.
        • Hoofnagle J.H.
        From non-A, non-B hepatitis to hepatitis C virus cure.
        J Hepatol. 2015; 62: S87-S99
        • Pearlman B.L.
        • Traub N.
        Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
        Clin Infect Dis. 2011; 52: 889-900
      1. “Pamela Anderson says: I’m cured of Hep C”. Accessed December 2015.

      2. Your moment to cure. Viekira homepage. Accessed January 2016.

      3. I am hepatitis C cured. Sovaldi homepage. Accessed January 2016.

      4. Hepatitis C virus can be cured in 12 weeks with drug course: study. Accessed December 2015.

        • Maylin S.
        • Martinot-Peignoux M.
        • Moucari R.
        • Boyer N.
        • Ripault M.P.
        • Cazals-Hatem D.
        • et al.
        Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
        Gastroenterology. 2008; 135: 821-829
        • Thein H.
        • Yi Q.
        • Dore G.J.
        • Krahn M.D.
        Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.
        Hepatology. 2008; 48: 418-431
        • El-Serag H.B.
        Hepatocellular carcinoma and hepatitis C in the United States.
        Hepatology. 2002; 36: S74-S83
        • Aspinall E.
        • Hutchinson S.J.
        • Janjua N.S.
        • Grebley J.
        • Yu A.
        • Alavi M.
        • et al.
        Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
        J Hepatol. 2015; 62: 269-277
        • Negro F.
        • Forton D.
        • Craxi A.
        • Sulkowski M.S.
        • Feld J.J.
        • Manns M.P.
        Extrahepatic morbidity and mortality of chronic hepatitis C.
        Gastroenterology. 2015; 149: 1345-1360
        • Simmons B.
        • Saleem J.
        • Heath K.
        • Cooke G.S.
        • Hill A.
        Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response.
        Clin Infect Dis. 2015; 61: 730-740
        • Lambert P.C.
        • Thompson J.R.
        • Weston C.L.
        • Dickman P.W.
        Estimating and modelling the cure fraction in population-based cancer survival analysis.
        Biostatistics. 2007; 8: 576-594
        • Del Maso L.
        • Guzzinati S.
        • Buzzoni C.
        • Capocaccia R.
        • Serraino D.
        • Caldarella A.
        • et al.
        Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types.
        Ann Oncol. 2014; 25: 2251-2260
        • Van der Meer A.J.
        • Wedemeyer H.
        • Feld J.J.
        • Dufour J.F.
        • Zeuzem S.
        • Hansen B.E.
        • et al.
        Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.
        JAMA. 2014; 312: 1927-1928
        • Bruno S.
        • Di Marco V.
        • Iavarone M.
        • Roffi L.
        • Crosignani A.
        • Calvaruso V.
        • et al.
        Survival of patients with HCV cirrhosis and sustaeind virologic response is similar to the general population.
        J Hepatol. 2016; 64: 1217-1223
        • Razavi H.
        • Waked I.
        • Sarrazin C.
        • Myers R.P.
        • Idilman R.
        • Calinas F.
        • et al.
        The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm.
        J Viral Hepat. 2014; 21: 34-59
        • Innes H.A.
        • McDonald S.A.
        • Dillon J.F.
        • Allen S.
        • Hayes P.C.
        • et al.
        Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
        Hepatology. 2015; 62: 355-364
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Lin Z.H.
        • Xin Y.N.
        • Dong Q.J.
        • Wang Q.
        • Jiang X.J.
        • Zhan S.H.
        • et al.
        Performance of the aspartate aminotransferase-to-platelet-ratio index for the stage of hepatitis C-related fibrosis: an updated meta-analysis.
        Hepatology. 2011; 53: 726-736
        • Innes H.A.
        • Hutchinson S.J.
        • Allen S.
        • Bhattacharyya D.
        • Bramley P.
        • Carman B.
        • et al.
        Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland.
        Eur J Gastroenterol Hepatol. 2012; 24: 646-655
        • Sewell J.L.
        • Stick K.M.
        • Monto A.
        Hepatocellularcarcinoma after sustained virologic response in hepatitis C patients with cirrhosis on a pretreatment liver biopsy.
        Eur J Gastroenterol Hepatol. 2009; 21: 225-229
        • Hirashima N.
        • Mizokami M.
        • Orito E.
        • Koide T.
        • Itazu I.
        • Kamuda K.
        • et al.
        Case report: development of hepatocellular carcinoma in a patients with chronic hepatitis C infection after a complete and sustained response to interfetron-alpha.
        J Gastroenterol Hepatol. 1996; 11: 955-958
        • Scherzer T.M.
        • Reddy K.R.
        • Wrba F.
        • Hofer H.
        • Staufer K.
        • Steindl-Munda P.
        • et al.
        Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C.
        J Viral Hepat. 2008; 15: 659-665
        • Tabibian J.H.
        • Landaverde C.
        • Winn J.
        • Geller S.A.
        • Nissen N.N.
        Hepatocellular carcinoma in a hepatitis C patients with sustained viral response and no fibrosis.
        Ann Hepatol. 2009; 8: 64-67
        • Nagaoki Y.
        • Aikata H.
        • Nakano N.
        • Shinohara F.
        • Nakamura Y.
        • Hatooka M.
        • et al.
        Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study.
        J Gastroenterol Hepatol. 2015;
        • Innes H.A.
        • Hutchinson S.J.
        • Allen S.
        • Bhattacharyya D.
        • Bramley P.
        • Delahooke T.E.
        • et al.
        Excess liver-related morbidity of chronic hepatitis C patients who achieve a sustained viral response and are discharged from care.
        Hepatology. 2011; 54: 1547-1558
        • Omland L.H.
        • Christensen P.B.
        • Krarup H.
        • Jepson P.
        • Weis N.
        • Sorensen H.T.
        • et al.
        Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study.
        PLoS ONE. 2011; 6: e22476
        • Omland L.H.
        • Osler M.
        • Jepsen P.
        • Krarup H.
        • Weis N.
        • Christensen P.B.
        • et al.
        Socioeconomic status in HCV infected patients – risk and prognosis.
        Clin Epidemiol. 2013; 5: 163-172
        • El-Serag H.B.
        • Kanwal F.
        • Richardson P.
        • Kramer J.
        Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection.
        Hepatology. 2016; 64: 130-137
      5. Stephan Wiktor. Hepatitis B and C public policy association meeting: EU HCV Brussels, 17th February 2016. (accessed April 2016).